Browse the evidence

Manipulating energy density does not significantly alter the total amount of food consumed (in grams), meaning volume intake remains constant.

Do not worry about shrinking your portions. When you lower the energy density of your food (e.g., by adding vegetables), you can eat the same amount of food by weight. This helps maintain satiety and makes the diet easier to follow long-term.

Management of insulin resistance through lifestyle interventions (diet and exercise) and pharmacological agents is effective, although no medication is currently specifically approved solely for treating insulin resistance.

Focus on sustainable lifestyle changes: eat a balanced diet and exercise regularly. These are the proven ways to manage insulin resistance. Do not wait for a specific 'IR medication' as none exists; use existing tools like Metformin only if prescribed for diabetes or other conditions.

Government-imposed pandemic containment strategies, including lockdowns and social distancing, cause a significant decline in physical activity across all age groups and genders.

Pandemic restrictions significantly reduce physical activity for most people, regardless of age or gender. To mitigate this, seek out alternative forms of exercise like digital training or home workouts, as maintaining activity is crucial for preventing negative health outcomes during lockdowns.

Digital Cognitive-Behavioral Therapy for Insomnia (dCBT-I) is a cost-effective and viable method for delivering CBT-I at scale, potentially reducing healthcare expenditures.

If you cannot access a therapist for CBT-I, look for validated digital CBT-I programs. They are increasingly recognized as cost-effective and can provide the same core therapeutic benefits.

Females bear a disproportionately higher burden of malnutrition-related mortality and DALYs compared to males, while males experience higher obesity-related DALYs, indicating sex-specific vulnerabilities in the double burden of disease.

Nutrition and health policies must be sex-specific. Women face higher risks of malnutrition due to biological needs and social inequities in food access, while men face higher risks of obesity. Interventions should address these distinct vulnerabilities rather than using a one-size-fits-all approach.

Step intensity, specifically 'peak-30 cadence' (fastest 30 minutes of walking per day), provides additional risk reduction for mortality and morbidity beyond total step count.

Try to walk briskly for short bursts during your day. You don't need to exercise formally; just walk faster for 30 minutes total (consecutive or not). This 'peak-30' intensity adds extra protection against heart disease and cancer on top of just walking more steps.

There is no minimal threshold for cognitive benefit from exercise; any amount of physical activity is better than none, though clinically meaningful changes require ~724 METs-min/week.

You do not need to exercise for hours to see brain benefits. Even small amounts of activity help. However, to see significant, clinically meaningful improvements, aim for approximately 724 METs-min per week (e.g., 150 minutes of moderate activity).

The COVID-19 pandemic caused a significant overall decrease in physical activity and mobility, alongside a significant increase in sedentary behavior, across diverse global populations.

During periods of restricted mobility or facility closures, expect a significant drop in physical activity. To mitigate this, prioritize utilizing available outdoor spaces (parks, trails) or adapting home environments, as access to these resources is a key determinant of maintaining activity levels during crises.

Vigorous or moderate exercise significantly reduces the risk of sleep disturbance in individuals with severe sedentary behavior, although this benefit is not mediated by the measured blood-cell-based inflammatory biomarkers.

If you sit for more than 8 hours a day, doing 150 minutes of moderate or 75 minutes of vigorous exercise per week significantly lowers your risk of sleep problems. However, this benefit is specific to those with high sitting times; for those who are already active, the added benefit on sleep risk was not statistically significant in this study.

Step intensity (cadence) is positively correlated with step count and independently associated with lower risk of chronic diseases, though the relationship is less consistent than step count alone.

While total steps are the primary driver, walking faster (higher cadence) adds additional benefit. However, you do not need to obsess over speed; simply increasing your total daily steps will likely increase your average cadence and provide protection.

Spontaneous physical activity (SPA) and non-exercise activity thermogenesis (NEAT) are significant contributors to energy expenditure, regulated by hypothalamic nuclei such as the lateral hypothalamus (LH) and arcuate nucleus (ARC).

Increase your daily movement through small, spontaneous actions (fidgeting, standing, walking) known as NEAT. This can account for 10-20% of your daily calorie burn. Try to break up long periods of sitting with brief movements to support your metabolism.

Tirzepatide and semaglutide produce similar reductions in fasting appetite and ad libitum energy intake during lunch, indicating that differences in weight loss between the two drugs are not explained by appetite suppression alone.

Both tirzepatide and semaglutide reduce hunger and calorie intake similarly during lunch. However, tirzepatide leads to more fat loss. This suggests that tirzepatide might work through additional mechanisms, such as increasing energy expenditure or changing how fat is stored, rather than just making you feel less hungry than semaglutide does.

Increased sleep irregularity (defined as higher standard deviation of daily sleep duration) is associated with increased odds of incident obesity, essential hypertension, hyperlipidemia, major depressive disorder, and generalized anxiety disorder.

Focus on keeping your sleep schedule consistent. Going to bed and waking up at roughly the same time every day is critical for preventing obesity, hypertension, and depression, even if you are getting the recommended 7-9 hours of total sleep. Use wearable data to track your sleep regularity (consistency) rather than just total hours.

Early Time-Restricted Eating (eTRE) with an 8-hour window (8 am - 4 pm) does NOT produce significantly greater weight loss than a calorie-restricted Mediterranean diet (MedDiet) in adults with obesity.

Early time-restricted eating (8 am - 4 pm) with a 600-calorie deficit did not result in significantly greater weight loss than a standard Mediterranean diet in this study. You may not see extra benefits from this specific timing strategy.

Weight stigma and discrimination are significant behavioral and emotional mechanisms linking high body weight to psychological distress.

Recognize that weight stigma is a real and harmful social force, not a personal failing. Seek supportive environments and mental health resources that address the impact of discrimination.

Global sugar-sweetened beverage (SSB) intake among adults increased by 16% (0.37 servings/week) between 1990 and 2018, with the most dramatic increases occurring in Sub-Saharan Africa (+81.9%) and specific high-population countries like Nigeria and Ethiopia.

Track your weekly SSB servings. If you live in or travel to regions with rapidly rising intake (like Sub-Saharan Africa or parts of Asia), be aware that marketing is aggressively targeting these demographics. Aim to keep added sugars <5-10% of daily calories as recommended by national guidelines.

Social media promotion and celebrity endorsements of semaglutide (specifically Ozempic/Wegovy) for off-label weight loss directly drive global search interest and subsequent supply shortages, overriding regulatory approval timelines.

Search interest in weight loss drugs like semaglutide is currently driven more by social media trends and celebrity endorsements than by official medical approvals. If you are seeing a surge in interest or shortages, it is likely due to viral media content rather than a change in medical guidelines.

Point-of-care gastric ultrasound is an effective and objective method to assess gastric contents and guide anesthetic management for patients on GLP-1 agonists.

Anesthesiologists should consider using gastric ultrasound to check the stomach contents of patients on GLP-1 agonists before surgery. This helps decide whether to proceed with anesthesia or take extra precautions to prevent aspiration.

Intentional weight loss in individuals with Type 2 Diabetes (T2D) is not consistently associated with reduced mortality risk and may be associated with higher mortality in obese subgroups, whereas weight cycling (body weight variability) is consistently associated with significantly increased all-cause and cardiovascular disease mortality.

If you have Type 2 Diabetes, do not focus on weight loss as a primary goal for reducing mortality risk. Instead, prioritize increasing physical activity and improving cardiorespiratory fitness. Weight cycling (losing and regaining weight) is associated with higher mortality risk, so maintaining a stable weight while improving fitness is a safer and more effective strategy for longevity.

There is a significant disparity in medication initiation rates between diabetes and obesity indications, with 72.2% of diabetes prescriptions filled within 60 days compared to only 46.8% of obesity prescriptions.

If you are prescribed a GLP-1 for weight loss, be aware that you are less likely to fill the prescription than someone prescribed for diabetes. This is due to insurance coverage gaps, not a lack of desire to treat. Check your coverage status before the prescription is written to avoid delays.

High out-of-pocket costs for semaglutide create a socioeconomic barrier to access, resulting in significantly lower prescription rates among low-income individuals despite them having a higher prevalence of obesity.

If you are on a limited budget, the high out-of-pocket cost of semaglutide may prevent you from accessing it, even if you have obesity. This is a systemic issue where low-income individuals are undertreated. Advocacy for reimbursement or subsidies is needed to address this inequality.

Significant inequities exist in access to bariatric surgery in Australia, with lower rates in public hospitals, rural areas, and among males, despite similar or higher obesity prevalence in these groups.

Access to bariatric surgery in Australia is uneven, with rural residents, men, and those without private healthcare facing significant barriers. If you live in a rural area or are a man, be proactive in seeking information and support to overcome these barriers. Explore public sector options and discuss your specific situation with a healthcare provider.

A 12-month behavioral weight maintenance intervention following weight loss fails to provide long-term metabolic or weight benefits beyond the intervention period, as benefits disappear after the maintenance phase ends.

A one-year maintenance program after weight loss will not prevent long-term weight regain or metabolic decline once you stop the program. To maintain results, you likely need a strategy of repeated short-term interventions or continuous lifestyle management, as a single fixed-duration maintenance phase is insufficient for long-term success.

Diet and lifestyle interventions alone are insufficient for long-term obesity management, as they typically result in only ~3% sustained weight loss at 5 years and fail to reverse population-level obesity trends.

Do not rely on short-term diet and exercise programs for long-term weight control. The average outcome is minimal sustained loss (~3%). Recognize obesity as a chronic condition requiring long-term, multidisciplinary support (medical, behavioral, environmental) rather than a finite 'program' you complete.